InvestingPro Fair Value predicted Hims & Hers 50% drop

InvestingPro's Fair Value models predicted a 50% drop in Hims & Hers Health (HIMS) stock, which was trading at $55.50 in September 2025. The analysis determined the stock was overvalued by 44%, with a Fair Value of $31.00. Over the next 12 months, HIMS shares fell approximately 50% to $27.68, validating the accuracy of InvestingPro's valuation methodology.

Hims & Hers Health provides telehealth services and direct-to-consumer prescription medications, and at the time of the Fair Value analysis, the company reported strong fundamentals such as $2.01 billion in revenue, $158.64 million in EBITDA, and $0.88 in earnings per share. Despite these positive metrics, HIMS experienced extreme volatility in the preceding six months, including a 70.9% surge in May 2025 followed by a 36% decline in August.

The significant premium of $55.50 to the calculated intrinsic value of $31.00 demonstrated a clear valuation disconnect. InvestingPro's comprehensive valuation framework, which combines multiple methodologies including discounted cash flow models, comparable company analyses, and analyst consensus targets, proved highly accurate as the stock declined steadily throughout 2026, reaching the predicted Fair Value target of approximately $27.90 in September 2026.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.